Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

760 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
Pinto A, Caltagirone M, Battista M, Gazzoli GC, Patti C, Pennese E, De Lorenzo S, Pavone V, Merli M, Chiarenza A, Gorgone AG, Piazza F, Puccini B, Noto A, Arcaini L, De Filippi R, Zinzani PL, Ferreri AJM, Ladetto M, Ferrari S, Gritti G. Pinto A, et al. Among authors: zinzani pl. Br J Haematol. 2024 Dec;205(6):2219-2227. doi: 10.1111/bjh.19661. Epub 2024 Jul 22. Br J Haematol. 2024. PMID: 39039666 Free PMC article.
The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies.
Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L, Gianni AM, Cavalli F, Barbui T; International Extranodal Lymphoma Study Group (IELSG). Cortelazzo S, et al. Among authors: zinzani pl. Br J Haematol. 2002 Jul;118(1):218-28. doi: 10.1046/j.1365-2141.2002.03613.x. Br J Haematol. 2002. PMID: 12100151 Free article.
Mycosis fungoides.
Zinzani PL, Ferreri AJ, Cerroni L. Zinzani PL, et al. Crit Rev Oncol Hematol. 2008 Feb;65(2):172-82. doi: 10.1016/j.critrevonc.2007.08.004. Epub 2007 Oct 22. Crit Rev Oncol Hematol. 2008. PMID: 17950613 Review.
Enteropathy-associated T-cell lymphoma.
Ferreri AJ, Zinzani PL, Govi S, Pileri SA. Ferreri AJ, et al. Among authors: zinzani pl. Crit Rev Oncol Hematol. 2011 Jul;79(1):84-90. doi: 10.1016/j.critrevonc.2010.06.006. Epub 2010 Jul 23. Crit Rev Oncol Hematol. 2011. PMID: 20655757 Review.
Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Savage KJ, et al. Among authors: zinzani pl. Crit Rev Oncol Hematol. 2011 Sep;79(3):321-9. doi: 10.1016/j.critrevonc.2010.07.007. Epub 2010 Aug 10. Crit Rev Oncol Hematol. 2011. PMID: 20702104 Review.
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJM, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E. Conconi A, et al. Among authors: zinzani pl. Ann Oncol. 2011 Mar;22(3):689-695. doi: 10.1093/annonc/mdq416. Epub 2010 Sep 1. Ann Oncol. 2011. PMID: 20810546 Free article. Clinical Trial.
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.
Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S. Zinzani PL, et al. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12. doi: 10.1007/s00259-011-1916-8. Epub 2011 Sep 6. Eur J Nucl Med Mol Imaging. 2012. PMID: 21894546
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E. Rigacci L, et al. Among authors: zinzani pl. Ann Hematol. 2012 Jul;91(7):1013-22. doi: 10.1007/s00277-012-1422-5. Epub 2012 Feb 15. Ann Hematol. 2012. PMID: 22349722
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M. Zinzani PL, et al. Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29. Hematol Oncol. 2013. PMID: 23108928
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
760 results